Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 25054064)

1.

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.

Li M, Bolduc AR, Hoda MN, Gamble DN, Dolisca SB, Bolduc AK, Hoang K, Ashley C, McCall D, Rojiani AM, Maria BL, Rixe O, MacDonald TJ, Heeger PS, Mellor AL, Munn DH, Johnson TS.

J Immunother Cancer. 2014 Jul 7;2:21. doi: 10.1186/2051-1426-2-21. eCollection 2014.

2.

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP.

J Exp Med. 2013 Jul 1;210(7):1389-402. doi: 10.1084/jem.20130066. Epub 2013 Jun 10.

3.

Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.

Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, Nicholas S, Kellett M, Ruzevick J, Jackson C, Albesiano E, Durham NM, Ye X, Tran PT, Tyler B, Wong JW, Brem H, Pardoll DM, Drake CG, Lim M.

PLoS One. 2014 Jul 11;9(7):e101764. doi: 10.1371/journal.pone.0101764. eCollection 2014.

4.

Blocking IDO activity to enhance anti-tumor immunity.

Munn DH.

Front Biosci (Elite Ed). 2012 Jan 1;4:734-45. Review.

PMID:
22201909
5.

IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.

Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, Tobias AL, Han Y, Lesniak MS.

Clin Cancer Res. 2012 Nov 15;18(22):6110-21. doi: 10.1158/1078-0432.CCR-12-2130. Epub 2012 Aug 29.

6.

Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.

Tanizaki Y, Kobayashi A, Toujima S, Shiro M, Mizoguchi M, Mabuchi Y, Yagi S, Minami S, Takikawa O, Ino K.

Cancer Sci. 2014 Aug;105(8):966-73. doi: 10.1111/cas.12445. Epub 2014 Jun 27.

PMID:
24826982
7.

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH.

J Clin Invest. 2007 Sep;117(9):2570-82.

8.

The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.

Sørensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, Svane IM, Becker JC, thor Straten P, Andersen MH.

PLoS One. 2009 Sep 7;4(9):e6910. doi: 10.1371/journal.pone.0006910.

9.

Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy.

Mellor AL, Chandler P, Lee GK, Johnson T, Keskin DB, Lee J, Munn DH.

J Reprod Immunol. 2002 Oct-Nov;57(1-2):143-50. Review.

PMID:
12385839
10.

Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy.

Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, Munn DH.

Nat Immunol. 2001 Jan;2(1):64-8.

PMID:
11135580
11.

Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific.

Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL.

J Reprod Immunol. 2004 Apr;61(2):67-77.

PMID:
15063630
12.
13.

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH.

Cancer Res. 2007 Jan 15;67(2):792-801.

14.

Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses.

Mellor AL, Munn DH.

J Reprod Immunol. 2001 Oct-Nov;52(1-2):5-13. Review.

PMID:
11600174
15.

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ.

Int J Cancer. 2002 Sep 10;101(2):151-5.

PMID:
12209992
16.

Indoleamine 2,3-dioxygenase: is it an immune suppressor?

Soliman H, Mediavilla-Varela M, Antonia S.

Cancer J. 2010 Jul-Aug;16(4):354-9. doi: 10.1097/PPO.0b013e3181eb3343. Review.

17.

Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.

Ito H, Ando T, Arioka Y, Saito K, Seishima M.

Immunology. 2015 Apr;144(4):621-30. doi: 10.1111/imm.12413.

PMID:
25322876
18.

Anti-parasitic effector mechanisms in human brain tumor cells: role of interferon-gamma and tumor necrosis factor-alpha.

Däubener W, Remscheid C, Nockemann S, Pilz K, Seghrouchni S, Mackenzie C, Hadding U.

Eur J Immunol. 1996 Feb;26(2):487-92.

PMID:
8617321
19.

Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice.

Takamatsu M, Hirata A, Ohtaki H, Hoshi M, Ando T, Ito H, Hatano Y, Tomita H, Kuno T, Saito K, Seishima M, Hara A.

Cancer Sci. 2015 May 29. doi: 10.1111/cas.12705. [Epub ahead of print]

PMID:
26033215
20.

Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase.

Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold S, Adams E, Munn DH.

Int Immunol. 2004 Oct;16(10):1391-401. Epub 2004 Sep 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk